First Time Loading...

Haemato AG
XETRA:HAEK

Watchlist Manager
Haemato AG Logo
Haemato AG
XETRA:HAEK
Watchlist
Price: 21.4 EUR -1.83% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

HAEK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Haemato AG engages in the pharmaceutical industry. [ Read More ]

The intrinsic value of one HAEK stock under the Base Case scenario is 21.48 EUR. Compared to the current market price of 21.4 EUR, Haemato AG is Fairly Valued.

Key Points:
HAEK Intrinsic Value
Base Case
21.48 EUR
Fairly Valued
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Haemato AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling HAEK stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Haemato AG

Provide an overview of the primary business activities
of Haemato AG.

What unique competitive advantages
does Haemato AG hold over its rivals?

What risks and challenges
does Haemato AG face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Haemato AG.

Provide P/S
for Haemato AG.

Provide P/E
for Haemato AG.

Provide P/OCF
for Haemato AG.

Provide P/FCFE
for Haemato AG.

Provide P/B
for Haemato AG.

Provide EV/S
for Haemato AG.

Provide EV/GP
for Haemato AG.

Provide EV/EBITDA
for Haemato AG.

Provide EV/EBIT
for Haemato AG.

Provide EV/OCF
for Haemato AG.

Provide EV/FCFF
for Haemato AG.

Provide EV/IC
for Haemato AG.

Show me price targets
for Haemato AG made by professional analysts.

What are the Revenue projections
for Haemato AG?

How accurate were the past Revenue estimates
for Haemato AG?

What are the Net Income projections
for Haemato AG?

How accurate were the past Net Income estimates
for Haemato AG?

What are the EPS projections
for Haemato AG?

How accurate were the past EPS estimates
for Haemato AG?

What are the EBIT projections
for Haemato AG?

How accurate were the past EBIT estimates
for Haemato AG?

Compare the revenue forecasts
for Haemato AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Haemato AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Haemato AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Haemato AG compared to its peers.

Compare the P/E ratios
of Haemato AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Haemato AG with its peers.

Analyze the financial leverage
of Haemato AG compared to its main competitors.

Show all profitability ratios
for Haemato AG.

Provide ROE
for Haemato AG.

Provide ROA
for Haemato AG.

Provide ROIC
for Haemato AG.

Provide ROCE
for Haemato AG.

Provide Gross Margin
for Haemato AG.

Provide Operating Margin
for Haemato AG.

Provide Net Margin
for Haemato AG.

Provide FCF Margin
for Haemato AG.

Show all solvency ratios
for Haemato AG.

Provide D/E Ratio
for Haemato AG.

Provide D/A Ratio
for Haemato AG.

Provide Interest Coverage Ratio
for Haemato AG.

Provide Altman Z-Score Ratio
for Haemato AG.

Provide Quick Ratio
for Haemato AG.

Provide Current Ratio
for Haemato AG.

Provide Cash Ratio
for Haemato AG.

What is the historical Revenue growth
over the last 5 years for Haemato AG?

What is the historical Net Income growth
over the last 5 years for Haemato AG?

What is the current Free Cash Flow
of Haemato AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Haemato AG.

Financials

Balance Sheet Decomposition
Haemato AG

Current Assets 77.3m
Cash & Short-Term Investments 26.1m
Receivables 23.3m
Other Current Assets 27.9m
Non-Current Assets 106.1m
Long-Term Investments 10.9m
PP&E 3.8m
Intangibles 91.3m
Other Non-Current Assets 144k
Current Liabilities 31.4m
Accounts Payable 20.2m
Accrued Liabilities 766k
Other Current Liabilities 10.4m
Non-Current Liabilities 2.6m
Long-Term Debt 2.5m
Other Non-Current Liabilities 135k
Efficiency

Earnings Waterfall
Haemato AG

Revenue
260.8m EUR
Cost of Revenue
-241.1m EUR
Gross Profit
19.7m EUR
Operating Expenses
-10.6m EUR
Operating Income
9.2m EUR
Other Expenses
444.4k EUR
Net Income
9.6m EUR

Free Cash Flow Analysis
Haemato AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

HAEK Profitability Score
Profitability Due Diligence

Haemato AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive 1-Year Revenue Growth
Positive Gross Profit
Positive ROE
46/100
Profitability
Score

Haemato AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

HAEK Solvency Score
Solvency Due Diligence

Haemato AG's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
83/100
Solvency
Score

Haemato AG's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HAEK Price Targets Summary
Haemato AG

Wall Street analysts forecast HAEK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HAEK is 34 EUR .

Lowest
Price Target
Not Available
Average
Price Target
34 EUR
59% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

HAEK Price
Haemato AG

1M 1M
-
6M 6M
+3%
1Y 1Y
+25%
3Y 3Y
-12%
5Y 5Y
-47%
10Y 10Y
-29%
Annual Price Range
21.4
52w Low
16.6026
52w High
28
Price Metrics
Average Annual Return -19.08%
Standard Deviation of Annual Returns 18.12%
Max Drawdown -69%
Shares Statistics
Market Capitalization 111.5m EUR
Shares Outstanding 5 210 387
Percentage of Shares Shorted
N/A

HAEK Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Haemato AG Logo
Haemato AG

Country

Germany

Industry

Health Care

Market Cap

111.5m EUR

Dividend Yield

5.61%

Description

Haemato AG engages in the pharmaceutical industry. The company is headquartered in Schoenefeld, Brandenburg. The company went IPO on 2012-03-26. The firm trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The firm's main markets are Europe, North America and Japan. The company also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The firm's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.

Contact

BRANDENBURG
Schoenefeld
Lilienthalstrasse 5c
+4930897308670.0
https://haemato.ag/

IPO

2012-03-26

Employees

169

Officers

MD & Member of Management Board
Mr. Attila Strauss

See Also

Discover More
What is the Intrinsic Value of one HAEK stock?

The intrinsic value of one HAEK stock under the Base Case scenario is 21.48 EUR.

Is HAEK stock undervalued or overvalued?

Compared to the current market price of 21.4 EUR, Haemato AG is Fairly Valued.